Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and its partner organisations have been awarded funding that will support the training of over 175 bioscience graduate students as part of £170 million investment in bioscience by the BBSRC (Biotechnology and Biosciences Research Council, part of UK Research and Innovation).

Oxford-led doctoral training partnership to offer over 175 graduate scholarships in the biosciences © Shutterstock

The total investment will fund 1,700 PhD researchers over five annual cohorts at academic institutions all over the UK under the third phase of UKRI-BBSRC’s Doctoral Training Partnerships (DTP). The Oxford Interdisciplinary Bioscience DTP’s share will be over £14M, and matched funding by partner organisations and industry will bring the total investment in the Oxford partnership to over £20 million

This represents the third phase of BBSRC funding for Oxford’s Interdisciplinary Bioscience DTP programme, an innovative four-year DPhil/PhD programme that aims to equip a new generation of researchers with the skills, insight and knowledge needed to tackle the most important challenges in bioscience research, and develop the world-class, highly skilled workforce the UK needs for its future. Oxford’s Interdisciplinary Bioscience DTP was initially funded in 2012 and is part of the University of Oxford’s innovative, interdisciplinary Doctoral Training Centre.

The Oxford Interdisciplinary Bioscience DTP is led by the University of Oxford, in partnership with eight world-class research organisations. Six of these collaborations, The Pirbright Institute, Oxford Brookes University, Diamond Light Source, ISIS Neutron and Muon Source, STFC Central Laser Facility and the Research Complex at Harwell, continue the successful partnership established in the second phase of DTP funding. For the third phase two new organisations have joined the partnership, the Novo Nordisk Research Centre Oxford (NNRCO), an innovative target discovery and translational research institute which opened in Oxford in 2017; and the Rosalind Franklin Institute, a new national institute based at Harwell dedicated to transforming life science through interdisciplinary research and technology development.

Read more (University of Oxford website)

Similar stories

Eoghan Mulholland receives prestigious Lee Placito Research Fellowship

Awards and Appointments General

Dr Eoghan Mulholland has received the prestigious Lee Placito Research Fellowship in Gastrointestinal Cancer. Eoghan will use this 3-year position to research cell interactions in colorectal cancers.

Eleven Oxford professors honoured by the Academy of Medical Sciences

Awards and Appointments General

The Academy of Medical Sciences has elected 11 University of Oxford biomedical and health scientists to its fellowship.

3,400 different medicines used globally to treat COVID-19

Coronavirus COVID-19 General Research

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study.

Children and Adolescents’ Mental Health: One Year On

Coronavirus COVID-19 General Research

Parents and carers reported that behavioural, emotional and attentional difficulties in their children changed considerably throughout the past year, increasing in times of national lockdown and decreasing as restrictions eased and schools reopened, according to the latest Co-SPACE (COVID-19 Supporting Parents, Adolescents, and Children in Epidemics) study, led by experts at the University of Oxford.

Future-Proofing Mental Health

General Research

UK academics are calling for targets for mental health research in order to meet the healthcare challenges of the next decade. Published today in Journal of Mental Health, researchers set out four overarching goals that will speed up implementation of mental health research and give a clear direction for researchers and funders to focus their efforts when it comes to better understanding the treatment of mental health.

Promising malaria vaccine enters final stage of clinical testing in West Africa

Clinical Trials General Research

First vaccinations have now begun in Mali in a phase III trial of a malaria vaccine developed at the University of Oxford. Known as R21/Matrix-M, it recently showed efficacy of 77% over 12 months in a phase IIb trial, and it is hoped that this phase III trial will help to lead to licensure of this malaria vaccine by 2023.